Delos Capital
Finance · China · 11-50 Employees
View Company Info for Free
Overview
Headquarters
Hong Kong, Central and Western, ChinaPhone Number
+852 34629510Website
www.deloscapital.comRevenue
$5.9 MillionIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
1
1
1
1
1
1
About Delos Capital
Delos Capital is a biotech venture capital firm that invests in life science, biotech, and medtech companies focused on transforming innovative ideas into medical breakthroughs. The firm empowers leaders in the life sciences sector by leveraging a diverse skill set and a global network to support groundbreaking innovations aimed at improving global health. Their portfolio includes companies developing next-generation therapies, innovative therapeutics for inflammatory and immunology conditions, and mRNA-based genetic medicines. Delos Capital is committed to making a positive and lasting impact on human health through strategic investments in extraordinary science and inspiring teams.Explore more
Delos Capital Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Delos Capital your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Website visits: Recent activity has been detected on your website
Product Launch: Get notified when Delos Capital launches new products
Click to see if Delos Capital had a recent Job posting/layoffs
Check out if Delos Capital is spiking on competitors!
Check if Delos Capital has recently received funding, and reach out quickly before it becomes old news!
Congratulate Masked Content for being promoted to Masked Content at Delos Capital
Funding: Get notified immidiatlly once Delos Capital has new funding data
Earning: See what the market has to say on Delos Capital recently announced quarterly report
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Delos Capital, which may be a good buyer, showed buying intent in Masked Content Topic
Recommended Actions
Find VP level buyers at Delos Capital
Find 2 more new buyers
Company Profile Activity
Activity Insights
Delos Capital is experiencing very low activity levels compared to other companies in the Finance sector.
What does this means?
Delos Capital is drawing exceptional interest within the Finance industry, suggesting notable developments or strong market momentum, learn more about Delos Capital.
Delos Capital Tech Stack
A closer look at the technologies used by Delos Capital
See more technologies
Most Recent Scoops
Project
Spending/Investment
Project
Spending/Investment
Project
Spending/Investment
Project
Spending/Investment
Delos Capital News & Media
TRexBio Announces $84 Million Series B Financing to Advance Pipeline of First-in-Class Immunology Programs into Clinical Development
SOUTH SAN FRANCISCO--(BUSINESS WIRE)-- #DeepBiology--TRexBio Announces $84 Million Series B Financing to Advance Pipeline of First-in-Class Immunology Programs into Clinical DevelopmentZenas BioPharma Announces Upsized $200 Million Series C Financing to Advance Mid- and Late-Stage Immunology-Focused Clinical Development Programs
Financing led by SR One, NEA, Norwest Venture Partners, and Delos Capital with significant participation from Enavate Sciences, Longitude Capital, and other new and existing investors
Read more news
Top Finance Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Delos Capital
Sign Up For FreeTo access detailed company insights
Delos Capital is a biotech venture capital firm that invests in life science, biotech, and medtech companies focused on transforming innovative ideas into medical breakthroughs. The firm empowers leaders in the life sciences sector by leveraging a diverse skill set and a global network to support groundbreaking innovations aimed at improving global... Read More
